Arcus Biosciences (RCUS) Return on Sales (2017 - 2026)

Arcus Biosciences' Return on Sales history runs 10 years deep, the most recent figure standing at 0.08% for Q1 2026.

• On a quarterly basis, Return on Sales fell 4.0% year-over-year to 0.08% in Q1 2026; TTM through Mar 2026 was 0.02%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.01%, changed 0.0% from the prior year.
• Return on Sales eased to 0.08% in Q1 2026 per RCUS's latest filing, from 0.03% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q1 2024 and bottomed at 0.08% in Q1 2026.
• The 5-year median for Return on Sales is 0.03% (2023), against an average of 0.03%.
• Across the five-year window, Return on Sales advanced 6 bps in 2022 and declined 4 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.02% in 2022, then slumped by 194 bps to 0.06% in 2023, then jumped by 38 bps to 0.04% in 2024, then advanced by 11 bps to 0.03% in 2025, then slumped by 134 bps to 0.08% in 2026.
• Per Business Quant, the three latest RCUS Return on Sales figures stand at 0.08% (Q1 2026), 0.03% (Q4 2025), and 0.05% (Q3 2025).